دورية أكاديمية
Comparative efficacy and safety of Chinese patent medicines of iron deficiency anemia during pregnancy: A network meta-analysis.
| العنوان: | Comparative efficacy and safety of Chinese patent medicines of iron deficiency anemia during pregnancy: A network meta-analysis. |
|---|---|
| المؤلفون: | Zou JC; School of Chinese Medicine, Weifang Medical University, Weifang 261053, Shandong Province, China., Jia XL; School of Chinese Medicine, Weifang Medical University, Weifang 261053, Shandong Province, China., Wang HX; Traditional Chinese Medicine Department, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China. wsy852893@163.com., Su YJ; Traditional Chinese Medicine Department, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China., Zhu JY; Traditional Chinese Medicine Department, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong Province, China. |
| المصدر: | World journal of clinical cases [World J Clin Cases] 2024 Jun 26; Vol. 12 (18), pp. 3515-3528. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101618806 Publication Model: Print Cited Medium: Print ISSN: 2307-8960 (Print) Linking ISSN: 23078960 NLM ISO Abbreviation: World J Clin Cases Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014-: Pleasanton, CA : Baishideng Publishing Group Original Publication: Hong Kong, China : Baishideng Publishing Group Co., Limited, [2013]- |
| مستخلص: | Background: Iron deficiency anemia (IDA) is a prevalent nutritional disorder during pregnancy. Clinical studies indicate that incorporating Chinese patent medicines (CPMs) with oral iron (OI) in treating IDA in pregnancy can reduce adverse effects and improve clinical outcomes. Nonetheless, the comparative efficacy of different CPMs remains unclear. Aim: To assess the safety and effectiveness of different CPMs for treating IDA during pregnancy using network meta-analysis. Methods: We conducted a search for randomized controlled trials (RCTs) that combined CPM and OI for IDA treatment in pregnancy, spanning from 2013 to the present. Data analysis was performed using Rev Man 5.3 and Stata 14.0 on literature that satisfied the quality criteria. Results: The analysis included 45 RCTs, encompassing 4422 pregnant patients with IDA. Six CPMs were examined, including Shengxuebao Mixture, Shengxuening Tablets (SXN), Yiqi Weixue CPMs (YQWX), Jianpi Shengxue CPMs (JPSX), Yiqi Buxue Tablets, and Compound Hongyi Buxue Oral Liquid (FFHY). Findings indicated that FFHY + OI significantly improved the clinical effective rate. SXN + OI was most effective in boosting red blood cells counts and hemoglobin levels. YQWX + OI showed superior results in improving serum ferritin, and SXN + OI was most effective in increasing serum iron levels. JPSX + OI was optimal in reducing adverse pregnancy outcomes, while YQBX + OI effectively minimized adverse events. A cluster analysis suggested that SXN + OI could be the potentially optimal therapeutic regimen for IDA in pregnancy. Conclusion: This study demonstrates that the combination of OI with CPMs offers better outcomes than OI alone. Based on clinical efficacy and other measured outcomes, SXN + OI emerges as the most effective treatment modality for improving the health of pregnant patients with IDA. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | Hematol Oncol Clin North Am. 2011 Apr;25(2):241-59, vii. (PMID: 21444028) Lancet Glob Health. 2019 Dec;7(12):e1706-e1716. (PMID: 31708151) Microorganisms. 2020 Apr 18;8(4):. (PMID: 32325688) Haematologica. 2020 Jan 31;105(2):260-272. (PMID: 31949017) Free Radic Biol Med. 2019 Mar;133:254-261. (PMID: 29981833) Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142. (PMID: 31643080) Am J Hematol. 2016 Jun;91(6):590-3. (PMID: 26971581) BJOG. 2016 Sep;123(10):1654-62. (PMID: 26969482) Eur J Haematol. 2022 Dec;109(6):633-642. (PMID: 36153674) Lancet Glob Health. 2018 May;6(5):e548-e554. (PMID: 29571592) MMWR Recomm Rep. 1998 Apr 3;47(RR-3):1-29. (PMID: 9563847) Obstet Gynecol. 2021 Aug 1;138(2):e55-e64. (PMID: 34293770) Ann Nutr Metab. 2007;51(2):172-81. (PMID: 17536195) Matern Child Nutr. 2018 Feb;14 Suppl 1:. (PMID: 29493899) J Obstet Gynaecol Br Commonw. 1964 Dec;71:919-22. (PMID: 14243212) PLoS One. 2015 Feb 20;10(2):e0117383. (PMID: 25700159) Int J Gynaecol Obstet. 2023 Aug;162 Suppl 2:14-22. (PMID: 37538017) Reprod Health. 2018 May 2;15(1):72. (PMID: 29720206) Rev Panam Salud Publica. 2022 Dec 30;46:e112. (PMID: 36601438) BMJ. 2013 Jun 21;346:f3443. (PMID: 23794316) |
| فهرسة مساهمة: | Keywords: Chinese patent medicine; Compound Hongyi Buxue Oral Liquid; Jianpi Shengxue Chinese patent medicines; Network meta-analysis; Shengxuebao Mixture; Shengxuening Tablets; Yiqi Buxue Tablets; Yiqi Weixue Chinese patent medicines |
| تواريخ الأحداث: | Date Created: 20240710 Latest Revision: 20240711 |
| رمز التحديث: | 20240711 |
| مُعرف محوري في PubMed: | PMC11229903 |
| DOI: | 10.12998/wjcc.v12.i18.3515 |
| PMID: | 38983402 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2307-8960 |
|---|---|
| DOI: | 10.12998/wjcc.v12.i18.3515 |